Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 5/20 | 0.46 |
| ▸ | PARP4 | Q9UKK3 | 2/20 | 0.46 |
| ▸ | PARP1 | P09874 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.46 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.39 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.39 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.39 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14236756 | 0.87 | PARP10 (0.47) | PARP10PARP4PARP1CA1CA2 | |
| SCHEMBL11477030 | 0.83 | GRIA4 (0.49) | CA1CA2STAT3ACHEFFAR1 | |
| SCHEMBL11134845 | 0.81 | STAT3 (0.44) | STAT3ACHEHSD17B10FFAR1ALDH1A1 | |
| SCHEMBL5616922 | 0.81 | PARP10 (0.48) | PARP10PARP4PARP1CA1CA2 | |
| SCHEMBL1250863 | 0.81 | ALDH1A1 (0.50) | PARP10PARP4PARP1CA1CA2 | |
| SCHEMBL11135957 | 0.79 | FFAR1 (0.49) | HSD17B10FFAR1ALDH1A1KMT2APOLB | |
| SCHEMBL10241629 | 0.79 | ESR1 (0.53) | CA1CA2STAT3ACHEFFAR1 | |
| SCHEMBL14731823 | 0.79 | ACHE (0.67) | STAT3ACHEFFAR1ALDH1A1TSHR | |
| SCHEMBL11474803 | 0.78 | PARP10 (0.46) | PARP10PARP4PARP1CA1CA2 | |
| SCHEMBL9685562 | 0.78 | PARP10 (0.46) | PARP10PARP4PARP1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043337-A1 | Selective beta3 adrenergic agonists | RITO CHRISTOPHER J (US) | 2005-02-24 | — | — | US | disclosed |
| US-6686372-B2 | ANTIDIABETIC AGENTS; DIETETICS | ELI LILLY AND COMPANY | 2004-02-03 | — | — | US | disclosed |
| US-6617347-B1 | Substituted pyrazoles are treatment of Type II diabetes and obesity. | ELI LILLY AND COMPANY | 2003-09-09 | — | — | US | disclosed |
| US-6413991-B1 | ANTIDIABETIC AGENTS; DIETETICS | ELI LILLY AND COMPANY | 2002-07-02 | — | — | US | disclosed |
| US-6265581-B1 | REACTING SPECIFIED EPOXIDE AND AMINE, REACTING PRODUCT WITH ACID TO FORM ACID ADDITION SALT | ELI LILLY AND COMPANY | 2001-07-24 | — | — | US | disclosed |
| US-6140352-A | FOR AGONIZING THE BETA 3 ADRENERGIC RECEPTOR TO TREAT TYPE II DIABETES AND OBESITY | ELI LILLY AND COMPANY (US) | 2000-10-31 | — | — | US | disclosed |
| US-6093735-A | TREATMENT OF TYPE II DIABETES AND OBESITY | ELI LILLY AND COMPANY (US) | 2000-07-25 | — | — | US | disclosed |
| US-6060492-A | SIDE EFFECT REDUCTION | ELI LILLY AND COMPANY (US) | 2000-05-09 | — | — | US | disclosed |
| US-6046227-A | USEFUL IN THE TREATMENT OF TYPE II DIABETES AND OBESITY; A SUBSTITUTED PYRAZINE COMPOUND | ELI LILLY AND COMPANY (US) | 2000-04-04 | — | — | US | disclosed |
| US-5977154-A | OBESITY, DIABETES | ELI LILLY AND COMPANY (US) | 1999-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043337-A1 | Selective beta3 adrenergic agonists | ADRB3, ADRB2, ADRB1 | PARP10 3439/4885PARP4 2530/4885PARP1 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.